Medical Devices Series A Investors & VC Firms

1145 firms in this list, with a median first check of $500K. 237 of them lead rounds. Generated from verified public data and updated continuously.

Fund	FoxScore	HQ	Invests	Stage	Check	CRM
MI MIRAI SOUZOU	88🔒	Tokyo	JP	Pre-Seed–Growth	—	+ Add to CRM
OR Orbia Ventures EDSAMJMO6 people	88🔒	Boston	US	Seed–Growth	$1M – $6M	+ Add to CRM
GL Global BioAccess Fund BRLWLWTM11 people	88🔒	New York	US	Series A–Late Stage	$10M	+ Add to CRM
ND NDI GBHPLMMH14 people	88🔒	Cleveland	US	Seed–Series A	—	+ Add to CRM
GT GTAN | Angel to Series A Investments DSEKEFH12 people	88🔒	Waterloo	CA	Pre-Seed–Series A	$350K – $1.5M	+ Add to CRM
KI KIKK Capital JSBVJTFK6 people	88🔒	Roosendaal	NL	Seed–Series A	$540K – $1.6M	+ Add to CRM
LE Leva Capital EGMGAHBN15 people	88🔒	Toronto	CA	Pre-Seed–Series A	—	+ Add to CRM
NO Novalis Biotech JVWVKMJB9 people	88🔒	Ghent	BE	Pre-Seed–Series A	—	+ Add to CRM
VI Viola Credit AGEFIVAB12 people · Follows rounds	88🔒	London	GB	Pre-Seed–Late Stage	$2M – $50M	+ Add to CRM
ZO Zoic Capital NSNMAB15 people	88🔒	Seattle	US	Seed–Series A	—	+ Add to CRM
CA Catalyst Health Ventures DZJSDMJL8 people · Leads rounds	88🔒	Boston	US	Seed–Series C	$1M – $3M	+ Add to CRM
DR Draper Triangle JKMSTJZM5 people · Leads rounds	88🔒	Pittsburgh	US	Seed–Late Stage	$250K – $2M	+ Add to CRM
LA Launch Tennessee LC1 person	88🔒	Nashville	US	Pre-Seed–Series B	—	+ Add to CRM
EM Emergent Medical Partners, LLP KKRBTJKT4 people	88🔒	San Jose	US	Seed–Series A	—	+ Add to CRM
IL IL Ventures EFYHDHDE10 people	88🔒	Tel Aviv-Yafo	IL	Seed–Series A	$1M – $3M	+ Add to CRM
AN Angels Santé AJAGCMEP12 people	88🔒	Paris	FR	Pre-Seed–Series A	—	+ Add to CRM
CH China Growth Capital Leads rounds	88🔒	Beijing	CN	Pre-Seed–Series A	$1M – $55M	+ Add to CRM
FU FundWA AMDGDMES9 people · Leads rounds	88🔒	Mount Pleasant	AU	Seed–Series A	—	+ Add to CRM
SH Shepherd Ventures GCRPTSFD6 people · Leads rounds	88🔒	San Diego	US	Series A–Late Stage	$750K – $3M	+ Add to CRM
GR Grow Venture Partners DBFBISMA8 people · Leads rounds	88🔒	Barcelona	ES	Pre-Seed–Series A	$108K – $216K	+ Add to CRM
TA Takwin Ventures CPEMASHH14 people	88🔒	Haifa	IL	Seed–Series A	—	+ Add to CRM
AP APEX Ventures ARSHWNGB10 people	88🔒	Vienna	AT	Pre-Seed–Series A	$540K – $1.1M	+ Add to CRM
AV Avonmore Developments MBSBMS4 people · Leads rounds	88🔒	London	GB	Pre-Seed–Series A	$63K – $315K	+ Add to CRM
SE Seed Healthcare TPRHBLCC12 people	88🔒	Dorado	US	Pre-Seed–Series A	—	+ Add to CRM

MIRAI SOUZOU

TokyoPre-Seed–Growth

Orbia Ventures

BostonSeed–Growth$1M – $6M

EDSAMJMO6 people

Global BioAccess Fund

New YorkSeries A–Late Stage$10M

BRLWLWTM11 people

NDI

ClevelandSeed–Series A

GBHPLMMH14 people

GTAN | Angel to Series A Investments

WaterlooPre-Seed–Series A$350K – $1.5M

DSEKEFH12 people

KIKK Capital

RoosendaalSeed–Series A$540K – $1.6M

JSBVJTFK6 people

Leva Capital

TorontoPre-Seed–Series A

EGMGAHBN15 people

Novalis Biotech

GhentPre-Seed–Series A

JVWVKMJB9 people

Viola Credit

LondonPre-Seed–Late Stage$2M – $50M

AGEFIVAB12 people

Zoic Capital

SeattleSeed–Series A

NSNMAB15 people

Catalyst Health Ventures

BostonSeed–Series C$1M – $3M

DZJSDMJL8 people

Draper Triangle

PittsburghSeed–Late Stage$250K – $2M

JKMSTJZM5 people

Launch Tennessee

NashvillePre-Seed–Series B

LC1 person

Emergent Medical Partners, LLP

San JoseSeed–Series A

KKRBTJKT4 people

IL Ventures

Tel Aviv-YafoSeed–Series A$1M – $3M

EFYHDHDE10 people

Angels Santé

ParisPre-Seed–Series A

AJAGCMEP12 people

China Growth Capital

BeijingPre-Seed–Series A$1M – $55M

FundWA

Mount PleasantSeed–Series A

AMDGDMES9 people

Shepherd Ventures

San DiegoSeries A–Late Stage$750K – $3M

GCRPTSFD6 people

Grow Venture Partners

BarcelonaPre-Seed–Series A$108K – $216K

DBFBISMA8 people

Takwin Ventures

HaifaSeed–Series A

CPEMASHH14 people

APEX Ventures

ViennaPre-Seed–Series A$540K – $1.1M

ARSHWNGB10 people

Avonmore Developments

LondonPre-Seed–Series A$63K – $315K

MBSBMS4 people

Seed Healthcare

DoradoPre-Seed–Series A

TPRHBLCC12 people

Data sourced from public filings and firms' own websites — see our methodology.